• NYGC Eyes Permanent Home in Manhattan

    Jun 18, 2012, 18:55 PM by Michael Croft
    Wall Street Journal | The New York Genome Center is in the final stages of negotiating a deal for about 150,000 square feet at 101 Sixth Ave., in the SoHo neighborhood of Manhattan, signaling the home stretch for the center's six-month search for a permanent home.
    Full story

  • Ambry Genetics Catches the Clinical Sequencing Wave

    Jun 13, 2012, 09:00 AM by Michael Croft

    Bio-IT World | After launching its CLIA Exome sequencing service six months ago, Ambry Genetics has quietly dropped the price to $7,900 for a trio. But potentially cannabilizing a thriving molecular diagnostics business is far from the only thing that makes Ambry stand out.  

    Full story

  • Finish What We Started: Dietrich Stephan’s Silicon Valley Biosystems Opens Genome Interpretation Floodgates

    Jun 12, 2012, 14:00 PM by Michael Croft

    Bio-IT World | In an exclusive briefing with Bio-IT World, the co-founder of Navigenics, Dietrich Stephan, says he aims to “finish what we started” with the commercial launch of a new genome interpretation company, Silicon Valley Biosystems (SVBio). 

    Full story

  • June Free Trials and Downloads

    Jun 11, 2012, 01:30 AM by Michael Croft
    Bio-IT World | Free trials and downloads for June.
    Full story

  • Foundation Medicine, Novartis Partner for Clinical Trial Enrollment

    Jun 11, 2012, 01:00 AM by Michael Croft
    Foundation Medicine | Foundation Medicine and Novartis are partnering on cancer drug testing. Novartis plans to use Foundation's technology as part of its cancer trial enrollment process over the next three years, focusing on Phase 1 and 2 oncology clinical programs. 
    Full story

  • FDA Delays Decision on HIV Pill

    Jun 11, 2012, 00:05 AM by Michael Croft
    San Francisco Chronicle | FDA has announced a delay in its decision on Gilead Sciences' HIV-prevention pill, choosing to take another three months to review the application and supporting materials.
    Full story

  • Genentech Gets FDA Approval for Combo Treatment

    Jun 11, 2012, 00:00 AM by Michael Croft
    Xconomy | Genentech announced early results of a new drug targeting HER2-expressing cancers early last week, and later received FDA approval to market Perjeta in combination with Herceptin and Taxotere. 
    Full story

  • Fetal Sequencing Based on Mother's Blood, Father's Saliva

    Jun 7, 2012, 07:00 AM by Michael Croft
    New York Times | Researchers are now able to determine a fetus's entire genome from the mother's blood and the father's saliva. 
    Full story

  • David Ho Highlights Launch of Bio-IT Asia Conference

    Jun 6, 2012, 02:50 AM by Michael Croft
    Bio-IT World | SINGAPORE—Ten years after the launch of the Bio-IT World Conference & Expo series in Boston, the conference made its debut in Asia in the sparkling Marina Bay Sands convention center. The trio of speakers who opened the three-day meeting was veteran HIV researcher David Ho, bio-IT consultant Chris Dagdigian, and AstraZeneca bioinformatician Yaron Turpaz. 
    Full story

  • Does Thimerosal Prevent Autism? Epidemiology Gone Wild

    Jun 6, 2012, 02:40 AM by Michael Croft
    Bio-IT World | The Skeptical Outsider | Human beings are born pattern recognizers, part of the repertoire of survival skills that separates us from the beasts. We are programmed to spot relationships that we are looking for, sometimes when they're not even there. This occasionally causes us to leap to questionable conclusions that can wreak all sorts of havoc. 
    Full story

  • Quake Wins $500K Lemelson-MIT Prize

    Jun 6, 2012, 01:25 AM by Michael Croft
    Mass High Tech | Stephen Quake, Helicos co-founder and Stanford University professor, has been recognized as this year's Lemelson-MIT Prize winner. He is being recognized for his invention of an improved method for measuring the immune system along with other work. 
    Full story

  • Complete Genomics Cuts Jobs, Starts Review

    Jun 6, 2012, 01:10 AM by Michael Croft
    Bloomberg Businessweek | Complete Genomics is laying off about 20 percent of its workforce and has hired a financial adviser, Jeffries & Co., to help it explore various strategic options including a possible merger or sale of the company.
    Full story

  • What's In a Name?

    Jun 5, 2012, 00:00 AM by Michael Croft
    Xconomy | Biotech companies change their names for many reasons, some good, some questionable. Xconomy looks at the old and new names of several biotechs. 
    Full story

  • Best Practices: Safety Rules for ELNs

    Jun 4, 2012, 03:00 AM by Michael Croft
    Bio-IT World Best Practices | Keeping track of all of the safety rules for reactions and reagents was an overwhelming proposal, so the chemistry safety officers at Bristol-Myers Squibb recruited informatics help to see if there was another option. The resulting electronic laboratory notebook customization earned a best practices nod by the judges in the 2012 Bio-IT World Best Practices Awards competition. 
    Full story

  • Investing in the Abandoned

    Jun 4, 2012, 01:00 AM by Michael Croft
    Forbes | When it comes to investing, pharma might point the way to areas of high return--if you take a look at what the sector is abandoning. 
    Full story

  • Genomics-Enabled Prevention

    Jun 4, 2012, 01:00 AM by Michael Croft
    Forbes | Ronald Davis, director of the Stanford Genome Technology Center, believes the time to invest in genomics and personalized medicine is now. 
    Full story

  • Genentech's New and Improved Herceptin

    Jun 4, 2012, 00:00 AM by Michael Croft
    Xconomy | Genentech and ImmunoGen have released early results of an experimental drug, trastuzumab emtansine (T-DM1), that targets HER2-expressing breast cancers. The drug combines the targeting capabilities of Genetech's Herceptin with an additional tumor toxin thanks to a chemical linker from ImmunoGen. 
    Full story

  • Bio-IT World News Briefs: May

    Jun 1, 2012, 01:00 AM by Michael Croft
    Bio-IT World | News briefs and bits from the biotech industry in May.
    Full story

  • Cancer Survivor on N-of-One Direct-to-Patient Ombudsman Model

    May 31, 2012, 09:20 AM by Michael Croft
    Bio-IT World | The long-term success of cancer informatics company N-of-One will be shaped by its newly appointed CEO, strategic partnerships with companies like Foundation Medicine, and ultimately the experiences of cancer patients such as Elaine Waples. 
    Full story

  • The Human Protein Atlas at the GoldLab Symposium

    May 31, 2012, 02:00 AM by Michael Croft
    Bio-IT World | BOULDER, CO—Larry Gold, the founder and CEO of protein biomarker company SomaLogic, hosted a diverse and engaging group of speakers for the third annual GoldLab Symposium* on the future of health care and personalized medicine earlier this month. “Technology is only the penultimate step in successful innovation,” he said. 
    Full story